LXEO vs SO · $147.7M cap vs P/E 22, rev $4.91B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus Southern Company (SO) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
Southern Company (SO) is a utilities - regulated electric company listed on US.
LXEO does not have a complete income-statement cache yet.
Latest reported SO revenue for 2019-12-31 was $4.91B. Net income was $440.0M. Revenue was down 7.9% from 2018-12-31 to 2019-12-31. SO currently screens at market cap $101.55B and trailing P/E 22.1.
LXEO currently screens at market cap $147.7M. SO currently screens at market cap $101.55B and trailing P/E 22.1.
Not investment advice. Open the LXEO and SO stock pages for the full models.
Not investment advice.